Compare · BAX vs JNJ
BAX vs JNJ
Side-by-side comparison of Baxter International Inc. (BAX) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. BAX focuses on Medical/Dental Instruments, while JNJ focuses on Biotechnology: Pharmaceutical Preparations.
- JNJ is the larger of the two at $619.30B, about 44.3x BAX ($13.96B).
- Over the past year, BAX is up 17.1% and JNJ is up 49.6% - JNJ leads by 32.4 points.
- JNJ has been more active in the news (23 items in the past 4 weeks vs 8 for BAX).
- Both have 25 recent analyst ratings on file.
- Company
- Baxter International Inc.
- Johnson & Johnson
- Price
- $27.57+2.13%
- $256.49-0.28%
- Market cap
- $13.96B
- $619.30B
- 1M return
- +22.72%
- -0.99%
- 1Y return
- +17.14%
- +49.58%
- Industry
- Medical/Dental Instruments
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 8
- 23
- Recent ratings
- 25
- 25
Baxter International Inc.
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest BAX
- SEC Form 8-K filed by Baxter International Inc.
- Baxter International Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Baxter Announces Cash Tender Offers
- Baxter upgraded by Citigroup with a new price target
- SEC Form 10-Q filed by Baxter International Inc.
- Baxter International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Baxter Reports Second-Quarter 2026 Results
- Baxter International Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Baxter to Host Second-Quarter 2026 Financial Results Conference Call for Investors
- Baxter Publishes 2025 Sustainability Report Highlighting Refreshed Strategy, Ongoing Commitment to Drive Meaningful Impact
Latest JNJ
- SEC Form 13F-HR filed by Johnson & Johnson
- A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout
- Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference
- Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One
- Johnson & Johnson filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer
- Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation
- Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset
- Johnson & Johnson filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Covista Names Emily C. Chiu and Leslie Storms to its Board of Directors